Minerva Surgical’s (NASDAQ:UTRS – Get Rating) lock-up period is set to end on Wednesday, April 20th. Minerva Surgical had issued 6,250,000 shares in its public offering on October 22nd. The total size of the offering was $75,000,000 based on an initial share price of $12.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
A number of research analysts recently weighed in on the company. Zacks Investment Research lowered Minerva Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 12th. Piper Sandler decreased their target price on Minerva Surgical from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Wednesday, March 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Minerva Surgical currently has a consensus rating of “Buy” and a consensus target price of $11.70.
Shares of NASDAQ UTRS opened at $4.25 on Tuesday. The company has a current ratio of 3.29, a quick ratio of 2.60 and a debt-to-equity ratio of 0.89. The firm has a fifty day moving average price of $4.90. Minerva Surgical has a one year low of $4.00 and a one year high of $10.37.
About Minerva Surgical (Get Rating)
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. Minerva Surgical is based in SANTA CLARA, Calif.
- Get a free copy of the StockNews.com research report on Minerva Surgical (UTRS)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.